Dr. Singh Discusses Immunotherapy Study in GIST

Arun S. Singh, MD
Published: Thursday, Jan 25, 2018



Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

GIST is a rare group of tumors that can start anywhere in the gastrointestinal tract. The 2 most common locations are in the stomach and the small intestine. Traditionally, they are treated with surgery but more advanced GISTs are treated with tyrosine kinase inhibitors (TKIs).

Currently, there are 3 drugs that are FDA approved for the treatment of patients with GISTs, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga). However, there are new exciting compounds in clinical trials, says Singh.

The nivolumab combination study is one of the few immunotherapy studies in this space, explains Singh. The trial aims to determine the overall response rate of the combination compared to nivolumab alone.
 


Arun S. Singh, MD, Ronald Reagan UCLA Medical Center, discusses the rationale behind a randomized phase II study (NCT02880020) of nivolumab (Opdivo) monotherapy versus nivolumab with ipilimumab (Yervoy) in patients with metastatic or unresectable gastrointestinal stromal tumors (GIST).

GIST is a rare group of tumors that can start anywhere in the gastrointestinal tract. The 2 most common locations are in the stomach and the small intestine. Traditionally, they are treated with surgery but more advanced GISTs are treated with tyrosine kinase inhibitors (TKIs).

Currently, there are 3 drugs that are FDA approved for the treatment of patients with GISTs, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga). However, there are new exciting compounds in clinical trials, says Singh.

The nivolumab combination study is one of the few immunotherapy studies in this space, explains Singh. The trial aims to determine the overall response rate of the combination compared to nivolumab alone.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
Publication Bottom Border
Border Publication
x